Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.
Read the full article on WikipediaRelapsed or refractory Acute Myeloid Leukaemia Clinical criteria: Treatment Phase: Initial treatment The treatment must be the sole PBS-subsidised therapy for this condition, AND The condition must not be acute promyelocytic leukaemia, AND The condition must be internal tandem duplication (ITD) and/or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive before initiating this drug for this condition, confirmed through a pathology report from an Approved Pathology Authority, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 prior to treatment initiation, AND The treatment must not be for maintenance therapy post-transplant. The prescriber must confirm whether the patient has FLT3 ITD or TKD mutation. The test result and date of testing must be provided at the time of application and documented in the patient's file.
“Gilteritinib acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.”
Working under the parallel aged-care framework? Aged-care equivalent →